FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileProShares - Ultra Nasdaq Biotechnology
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
BIB
ProShares - Ultra Nasdaq Biotechnology ETF AnalysisComprehensive ETF analysis for ProShares - Ultra Nasdaq Biotechnology (BIB) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisBIB
BIB
ProShares - Ultra Nasdaq Biotechnology
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
BIB
  1. Home
  2. Screener
  3. ProShares - Ultra Nasdaq BiotechnologyBIBETF

ProShares - Ultra Nasdaq Biotechnology

ETF
🇺🇸BIB•NASDAQ•Equity
Fund size (USD)
$102.23M
Expense Ratio
1.17%
Yield (12 mo)
0.10%
Holdings
274

Your view on BIB

ProShares - Ultra Nasdaq Biotechnology

ETFProShares
🇺🇸BIB•NASDAQ•Equity
Fund size (USD)
$102.23M
Expense Ratio
1.17%
Yield (12 mo)
0.10%
Holdings
274
Your view
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

ProShares - Ultra Nasdaq Biotechnology (BIB) is an Equity fund from ProShares, listed since 2010, with $102.2M in assets under management, a 1.17% expense ratio and a NAV of $116.17 USD.

Overview for ProShares - Ultra Nasdaq Biotechnology

Fund Type
ETF
Fund Issuer
ProShares
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
April 7, 2010
Domicile
US
Website
proshares.com/our-etfs/leveraged-and-inverse/bib
Fund Type
ETF
Fund Issuer
ProShares
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
April 7, 2010
Domicile
US
Website
proshares.com/our-etfs/leveraged-and-inverse/bib
Fund Type
ETF
Fund Issuer
ProShares
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
April 7, 2010
Domicile
US
Website
proshares.com/our-etfs/leveraged-and-inverse/bib

About this fund

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index.

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

1.17%

Yield (12 mo)

0.10%

Fund size

$102.23M

Fund Details

NAV$116.17 USD
Holdings274
Average Volume9.7K
Inception DateApril 7, 2010
Asset ClassEquity
Fund IssuerProShares
DomicileUS
ISINUS74347R2141
CUSIP74347R214
NAV CurrencyUSD

Expense Ratio

1.17%

Dividend Yield (TTM)

0.10%

Assets Under Management

$102.23M

NAV

$116.17 USD

Holdings

274

Average Volume

9.7K

Inception Date

April 7, 2010

Asset Class

Equity

Fund Issuer

ProShares

Domicile

US

ISIN

US74347R2141

CUSIP

74347R214

NAV Currency

USD

Expense Ratio

1.17%

Dividend Yield (TTM)

0.10%

Assets Under Management

$102.23M

NAV

$116.17 USD

Holdings

274

Average Volume

9.7K

Inception Date

April 7, 2010

Asset Class

Equity

Fund Issuer

ProShares

Domicile

US

ISIN

US74347R2141

CUSIP

74347R214

NAV Currency

USD

Distributions · last 12 months

Semi-Annual · 3 payments

Ex-datePaidAmount
Sep 23, 2026Sep 29, 2026$0.0413
Mar 25, 2026Mar 31, 2026$0.0036
Dec 24, 2025Dec 31, 2025$0.0673
Total, 12 months$0.11 a share

Dividend yield (TTM) 0.10% = $0.11 paid per share in the 12 months to Nov 20, 2026 ÷ the $108.38 price. Past distributions; future payments can differ.

Data last updated: Nov 14, 2026, 08:10 AM

Sectors

How the fund's assets are split across sectors.

3 sectors
  • 1Healthcare
    62.8%
  • 2Cash & Others
    21.5%
  • 3Government
    15.6%

Top sector

Healthcare

Top weight

62.8%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

253 positions
1IQMMPROSHARES GENIUS MNY MKT ETF
18.20%
2—Net Other Assets (Liabilities)
15.55%
3GILDGILEAD SCIENCES INC
6.24%
4AMGNAMGEN INC
5.57%
5VRTXVERTEX PHARMACEUTICALS INC
5.24%
6REGNREGENERON PHARMACEUTICALS
4.19%
7MRNAMODERNA INC
3.57%
8BIIBBIOGEN INC
1.64%
9RVMDREVOLUTION MEDICINES INC
1.53%
10INSMINSMED INC
1.42%
11ILMNILLUMINA INC
1.36%
12RPRXROYALTY PHARMA PLC- CL A
1.35%
13ROIVROIVANT SCIENCES LTD
1.26%
14ARGXARGENX SE - ADR
1.15%
15UTHRUNITED THERAPEUTICS CORP
1.08%

Concentration

Top 10 Weight63.15%
1IQMMPROSHARES GENIUS MNY MKT ETF
18.20%
2—Net Other Assets (Liabilities)
15.55%
3GILDGILEAD SCIENCES INC
6.24%
4AMGNAMGEN INC
5.57%
5VRTXVERTEX PHARMACEUTICALS INC
5.24%
6REGNREGENERON PHARMACEUTICALS
4.19%
7MRNAMODERNA INC
3.57%
8BIIBBIOGEN INC
1.64%
9RVMDREVOLUTION MEDICINES INC
1.53%
10INSMINSMED INC
1.42%
11ILMNILLUMINA INC
1.36%
12RPRXROYALTY PHARMA PLC- CL A
1.35%
13ROIVROIVANT SCIENCES LTD
1.26%
14ARGXARGENX SE - ADR
1.15%
15UTHRUNITED THERAPEUTICS CORP
1.08%

Top 10 Weight

63.15%

1IQMMPROSHARES GENIUS MNY MKT ETF
18.20%$17.02M
2—Net Other Assets (Liabilities)
15.55%$14.54M
3GILDGILEAD SCIENCES INC
6.24%$5.84M
4AMGNAMGEN INC
5.57%$5.21M
5VRTXVERTEX PHARMACEUTICALS INC
5.24%$4.90M
6REGNREGENERON PHARMACEUTICALS
4.19%$3.92M
7MRNAMODERNA INC
3.57%$3.34M
8BIIBBIOGEN INC
1.64%$1.53M
9RVMDREVOLUTION MEDICINES INC
1.53%$1.43M
10INSMINSMED INC
1.42%$1.32M
11ILMNILLUMINA INC
1.36%$1.27M
12RPRXROYALTY PHARMA PLC- CL A
1.35%$1.27M
13ROIVROIVANT SCIENCES LTD
1.26%$1.18M
14ARGXARGENX SE - ADR
1.15%$1.08M
15UTHRUNITED THERAPEUTICS CORP
1.08%$1.01M

Top 10 Weight

63.15%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on20 funds
FundAsset classExpense ratioAssetsHoldings
BIBProShares - Ultra Nasdaq BiotechnologyThis fundEquity1.17%$102M274

Comparable funds

  • BKSEBNY Mellon US Small Cap Core Equity ETFEquity0.04%$83M598
  • CAMXCambiar Aggressive Value ETFEquity0.59%$69M10
  • DIVLMadison Dividend Value ETFEquity0.65%$64M40
  • GOPUnusual Whales Subversive Republican Trading ETFEquity0.73%$87M0
  • ITDCiShares LifePath Target Date 2035 ETFMulti-Asset0.10%$125M12
  • NACPImpact Shares NAACP Minority Empowerment ETFEquity0.49%$74M10
  • RSEERareview Systematic Equity ETFEquity3.03%$70M9
  • SNTHMRP SynthEquity ETFEquity0.95%$257M0

More ProShares ETFs

  • EQQQProshares Ultra Qqq Equal WeightEquity1.12%$4M0
  • EQRRProShares - Equities for Rising Rates ETFEquity0.35%$34M52
  • ETHDProShares - UltraShort Ether ETFAlternatives0.95%$61M3
  • ETHTProShares - Ultra Ether ETFAlternatives0.96%$188M2
  • EUDVProShares - MSCI Europe Dividend Growers ETFEquity0.55%$9M47
  • EUMProShares Short MSCI Emerging MarketsEquity1.75%$18M9
  • EUOProShares UltraShort EuroAlternatives0.95%$39M3
  • EWVProShares UltraShort MSCI JapanEquity2.28%$5M5
  • EZJProShares Ultra MSCI JapanEquity2.46%$9M9
  • FBProShares S&P 500 Dynamic Buffer ETFEquity0.58%$4M0
  • FXPProShares UltraShort FTSE China 50Equity2.36%$5M11
  • GLLProShares UltraShort GoldCommodities0.95%$89M5
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.